AstraZeneca Signs Respiratory Drug Licensing Deal with CSPC, Worth Up to $1.9 Billion
Miles Bennett
AstraZeneca licensed the ex-China rights to CSPC's respiratory drug TQC3721 for up to $1.9 billion, marking another landmark deal as multinationals accelerate their sweep of China's innovative drug pipeline.
What exactly did AstraZeneca buy?
AstraZeneca gained exclusive rights to develop, manufacture, and commercialize Chia Tai Tianqing's PDE3/4 inhibitor TQC3721 outside China.
PDE3/4 inhibitors — drugs that block specific enzymes to relax airway muscles and reduce inflammation — target chronic respiratory diseases.
This means → AstraZeneca is not buying a finished product. It is buying a pipeline asset with potential but no overseas clinical proof yet.
How is the money structured?
CSPC Pharmaceutical (中国生物制药) receives $200 million upfront, with milestone payments capped at a combined $1.9 billion.
After launch, CSPC will also earn tiered royalties up to high single-to-low double-digit percentages on annual net sales.
In plain terms = the $200 million is a deposit. The remaining $1.7 billion only materializes if the drug clears each clinical hurdle, wins approvals, and generates real revenue.
How did the market react?
After the announcement, CSPC's Hong Kong-listed shares rose as much as 6.8% intraday, then gave back roughly half the gain.
This reflects the market pricing in the deal's signal value while remaining cautious about whether the full $1.9 billion will ever be realized.
The key question ahead: can TQC3721 hit its overseas clinical and commercial milestones — each one is effectively a repricing event.
What does this deal signal for the broader trend?
This is CSPC's second out-licensing deal this year; it signed a collaboration with Sanofi in February.
Multinational pharma companies are actively sweeping China's innovative drug pipeline, attracted by faster R&D timelines and lower costs.
This means → Chinese pharma is shifting from "generic-drug exporter" to "innovative-drug licensor" — a fundamental change in role.
Content is for reference only, not financial advice.